Directrices y guías de consenso para el manejo de la nefropatía diabética: ¿Son realmente válidas?

Nefrologia

Volumn 25, Issue SUPPL.4, 2005, Pages 28-33

  Castelao, Albert Martínez ^a   de Alvaro F ^b   Gorriz J L ^c   Gonzalez M T ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONSENSUS; DIABETIC NEPHROPATHY; HUMAN; PRACTICE GUIDELINE;

CONSENSUS; DIABETIC NEPHROPATHIES; HUMANS; PRACTICE GUIDELINES;

EID: 84858083878     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. McKinlay J, Marceasu L US public health and the 21st century: diabetes mellitus. Lancet 356: 757-761, 2000.
2. Goday A: Epidemiología de la diabetes y sus complicaciones no coronarias. Rev Esp Cardiol 55: 234-241, 2002.
3. Nefropatía diabética: Estudio farmaco-económico de la terapia con captopril. EMISA, Madrid, 1997.
4. Breyer JA: Diabetic nephropathy in insulin-dependent patients. Am J Kid Dis 20: 533-547, 1992.
5. Mogensen CE, Christiensen CK, Vittinghus E: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32 (Supl. 2): 64-78, 1983.
6. Mogensen CE The kidney in diabetes: how to control renal and related cardiovascular complications. Am J Kidney Dis 37 (Supl. 2): s2-s6, 2001.
7. Documento de Consenso sobre pautas de detección y tratamiento de la nefropatía Diabética en España: Sociedades Españolas de Diabetes, Endocrinología, Medicina Familiar y Comunitaria, y Nefrología. Nefrología 17 (6): 467-474, 1997.
8. Documento de Consenso 2002 sobre Pautas de Detección, Prevención y Tratamiento de la Nefropatía Diabética en España: Grupo Español de Estudio de la Nefropatía Diabética. Asociación Española de Nefrología Pediátrica, SED, SEEN, SEH-LELHA, SEMFYC, SEMERGEN, SEN. Nefrología 22: 521-530, 2002.
9. Hansson L, Zanchetti A, Carruthers G y cols.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755-1762, 1998.
10. Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br M J 317: 703-713, 1998.
11. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluations (HOPE) Study Investigators. Lancet 355: 253-259, 2000.
12. Parving HH, Lehnert H, Bröchner-Mortensen J y cols., for the Irbesartan in Patients with Type-2 Diabetes and Microalbuminuria Study Group: the effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
13. Lewis E J, Hunsicker LG, Clarke W y cols., for the Collaborative Study Group. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (12): 851-860, 2001.
14. Brenner BM, Cooper ME, De Zeew D y cols., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
15. Chobanian AV, Bakris GL, Black HR y cols.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 report. JAMA 289: 2560-2572, 2003.
16. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053, 2003.
17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-62, 1993.
18. ADA: American Diabetes Association. Clinical Practice Recommendations 2002. Diabetes Care 25 (Supl. 1): s1-s147, 2002.
19. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17: 1019-1024, 2002.
20. Mogensen CE, Neldam S, Tikkanen I y cols.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 321: 1440-1444, 2000.
21. Martínez Castelao A, Górriz JL, De Álvaro F y cols.: Morbidity and mortality factors in chronic renal disease in diabetic and non diabetic patients (MIRENA study). Preliminary results. J Am Soc Nephrol 15: 324 A, 2004.
22. Martínez Castelao A, Górriz JL, De Álvaro F, Lens XM, Martínez I: Influence of an early treatment of anemia with r-Hu-EPO alfa on the quality of life and nephropathy progression in type-2 diabetes mellitus patients (EPODIAB study). J Am Soc Nephrol 15: 865 A-866 A, 2004.
23. Martínez Castelao A, Ramos R, González MT, Castiñeiras MJ: Dyslipidemia and cardiovascular risk in type 2 diabetes mellitus patients with associated diabetic nephropathy. Nefrología 22 (Supl. 1): 51-58, 2002.
24. Ritz E: Consequences of late referral in diabetic renal disease. Acta Diabetol 39 (Supl. 1): S3-S8, 2002.
25. Górriz JL, Sancho A, Pallardó LM y cols.: Prognostic significance of programmed dialysis in patients whoinitiate renal substitutive treatment. Multicenter study in Spain. Nefrología 22: 49-59, 2002.
26. Gaede P, Vedel P, Larsen N y cols.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393, 2003.